

| No | 発表詳細 | 支援区分 |
|----|---|------------|
| 1 | Takeo A, Makari Y, Endo S, Matsuyama J, Kawabata R, Sugimoto N, Taniguchi H, Nagai K, Tamura S, Nishijima J, Ueda S, Kimura Y, Tamura T, Kobayashi K, Kawakami H, Fujitani K, Sakai D, Shimokawa T, Kurokawa Y Satoh T: Randomized, open-label, phase II study comparing five-weekly S-1 plus cisplatin (SP) with tri-weekly capecitabine plus cisplatin (XP) in chemotherapy-naïve patients with HER2 negative advanced gastric cancer (AGC): OGS1105 HERBIS-4A trial, 2018 Gastrical Cancers Symposium, American Society of Clinical Oncology, San Francisco, USA, 2018 | 外部研究支援[統計] |
| 2 | Kawada J, Imamura H, Matsuyama J, Fukui J, Nishikawa K, Kawase T, Shimokawa T, Kurokawa Y, Satoh T, Furukawa H: A phase II study to examine the effectiveness of nutritional support with elemental diet for stage II/III gastric cancer patients receiving adjuvant chemotherapy with S-1 (OGS1108), 2017 Gastrical Cancers Symposium, American Society of Clinical Oncology, San Francisco, USA, 2017 | 外部研究支援[統計] |
| 3 | Matsuyama J, Kurokawa Y, Nishikawa K, Kimura Y, Takeo A, Kawada J, Kawabata R, Makari Y, Tamura S, Doki Y, Sakai D, Shimokawa T, Satoh T: Randomized phase II study to compare docetaxel plus S-1 with cisplatin plus S-1 in advanced gastric cancer without measurable lesions (HERBIS-3), 2017 Gastrical Cancers Symposium, American Society of Clinical Oncology, San Francisco, USA, 2017. | 外部研究支援[統計] |
| 4 | Sugimoto N, Sakai D, Kawada J, Kawabata R, Nishikawa K, Kawase T, Oka Y, Shimizu T, Nishijima J, Hasegawa H, Endo S, Isozaki Y, Kimura Y, Matsuyama J, Kurokawa Y, Shimokawa T, Fujitani K, Satoh T.: A phase II trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer: OGS1203 (HERBIS-5), 2016 American Society of Clinical Oncology Annual Meeting, Cicago, USA, 2016 | 外部研究支援[統計] |
| 5 | Nishikawa K, Sakai D, Kawada J, Kawabata R, Kawase T, Oka Y, Sugimoto B, Shimizu T, Nishijima J, Hasegawa H, Endo S, Isozaki Y, Kimura Y, Matsuyama J, Kurokawa Y, Shimokawa T, Fujitani K, Satoh T:A phase II trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer : OGS1203 (HERBIS-5), 2016 Gastrical Cancers Symposium, American Society of Clinical Oncology, San Francisco, USA, 2016 | 外部研究支援[統計] |
| 6 | Yang HK, Kurokawa Y, Ryu HM, Cho H, Park SR, Masuzawa T, Lee HJ, Matsumoto S, Kwon OK, Honda H, Lee KH, Yamamoto K, Kong SH, Ishikawa T, Yook JH, Nabeshima K, Hahn S, Shimokawa T, Kang YK and Nishida T : A multinational phase II clinical trial of neoadjuvant imatinib for large gastrointestinal stromal tumor of the stomach, 2016 Gastrical Cancers Symposium, American Society of Clinical Oncology, San Francisco, USA, 2016 | 外部研究支援[統計] |
| 7 | Kawabata R, Sakai D, Kawada J, Nishikawa K, Kawase T, Oka Y, Sugimoto N, Shimizu T, Nishijima J, Hasegawa H, Endo S, Isozaki Y, Kimura Y, Matsuyama J, Kurokawa Y, Shimokawa T, Fujitani and Sato T : A phase II trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer : Osaka Gastrointestinal Cancer Chemotherapy Study Group OGS1203 (HERBIS-5), ESMO Asia Congress, Singapore, 2015 | 外部研究支援[統計] |